DSM launches new culture for stirred yogurts
DSM Food Specialties has launched DelvoFresh YS-140 culture for stirred yogurts to produce what the company says is “a creamy yogurt with a velvety mouthfeel and mild taste that consumers are after in today’s market.”
The new culture has a fast fermentation time and limited post-acidification at 5°C, meaning it maintains a mild taste during its entire shelf life. It is suitable for all types of stirred yogurts, including flavored or plain yogurt, as well as yogurts with added indulgent flavors such as fruit.
DairyReporter talks to Rolando Saltini, business manager for fermented milk products at DSM.
Saltini said, “Yogurt has quickly become a mainstay in the diets of many people. Yogurt can be a healthy breakfast, a high-protein pre- or post-workout snack, and it can be an indulgent snack or dessert. Our new DelvoFresh YS-140 is the culture in our range with the best balance between high creaminess and mild taste, delivering to the desire for more indulgence and enabling more yogurt moments in the day.”
Inbiose secures €4m in debt financing
Belgian biotech company Inbiose has entered into a €4m ($4.6m) debt agreement with BNP Paribas Fortis, one of the largest banks in Belgium.
The arrangement gives Inbiose access to non-dilutive financing to continue the development of its portfolio of HMOs and to drive them towards regulatory approval and market launch.
Last month Inbiose announced it is fast tracking seven HMOs from its portfolio for use in infant formula and health markets. Inbiose is looking to partner with industry segment leaders to accelerate registration and commercialization of HMOs into baby food, cosmetics, nutrition, pharma, dietary supplements and therapeutics.
In 2016, Inbiose entered into a collaboration with DuPont Nutrition & Health on fucosyllactose for human nutrition.
The product received the NutraIngredients-USA “Ingredient of the Year Award 2018” and is currently sold under the brand name Care4UTM both in infant formula as well as in health products.
Paul Decraemer, CFO, said, “This financing illustrates the confidence in our business case and its growth trajectory. Combined with the current cash balance, this debt facility enhances our flexibility to execute on the many opportunities we identify in the specialty carbohydrates market.”
Professor Wim Soetaert, CEO and chairman, said, “As we move into 2019, we will continue to evaluate all strategic opportunities to maximize the value of our state of the art GlycoActives technology platform. Securing debt finance helps us to achieve this goal.”
Inbiose extended its offering to seven HMOs for which efficient processes become available for large-scale manufacturing and commercialization.
The announcement marked the completion of a five-year strategic investment in developing the company’s GlycoActives platform to quickly develop cost-effective industrial fermentation processes to produce its ingredients.
In addition to fucosylated molecules 2’-fucosyllactose, 3-fucosyllactose and difucosyllactose, Inbiose technology is enabling large-scale production of Lacto-N-neo-tetraose (LNnT) and Lacto-N-tetraose (LNT) as well as the acidic HMOs 6’-sialyllactose (6’SL) and 3’-sialyllactose (3’SL).
Inbiose said the commercial availability of these HMOs will bring new opportunities to further improve infant milk formula and to get closer to the gold standard, human breast milk.
DairyReporter talked to Soetaert and the company’s chief commercial officer, Wesley Carpentier.